1
00:00:00,160 --> 00:00:04,160
Speaker 1: This is Bloomberg Business Week with Carol Masser and Bloomberg

2
00:00:04,240 --> 00:00:08,000
Speaker 1: Quick Takes Tim Stinovic from Bloomberg Radio. But last year

3
00:00:08,080 --> 00:00:09,800
Speaker 1: McKinsey came out with a report and they noted that

4
00:00:09,800 --> 00:00:12,799
Speaker 1: the bio economy could have a directing economic impact of

5
00:00:12,880 --> 00:00:15,480
Speaker 1: up to four trillion dollars a year over the next

6
00:00:15,480 --> 00:00:18,680
Speaker 1: ten to twenty years. One company working in that world

7
00:00:18,880 --> 00:00:24,439
Speaker 1: is in Scripta, Shri Kazaraja Cook. Let me try it again, Shrekazaraju.

8
00:00:25,000 --> 00:00:27,680
Speaker 1: He is president and CEO of the digital genome engineering

9
00:00:27,680 --> 00:00:30,680
Speaker 1: company that we just mentioned in Scripta and he joins

10
00:00:30,760 --> 00:00:33,080
Speaker 1: us on the phone in San Francisco Street. Forgive me

11
00:00:33,840 --> 00:00:37,040
Speaker 1: from the mispronunciation. It's what I can't even read my

12
00:00:37,080 --> 00:00:39,400
Speaker 1: own notes or fonetics. Um, but it is good to

13
00:00:39,400 --> 00:00:41,800
Speaker 1: have you here. And I have to say that my producer,

14
00:00:42,080 --> 00:00:44,639
Speaker 1: you bet, my producer and I were talking earlier that

15
00:00:44,760 --> 00:00:47,120
Speaker 1: this was just something that we love to talk about.

16
00:00:47,440 --> 00:00:49,840
Speaker 1: Tell us, first of all, um, how are you doing

17
00:00:50,000 --> 00:00:53,280
Speaker 1: what the past year has been like? Yeah? Well, first

18
00:00:53,320 --> 00:00:55,240
Speaker 1: of all, Carol, thanks for having me on. I'm a

19
00:00:55,320 --> 00:00:57,640
Speaker 1: big fan of Bloomberg Radio. I listened to it every morning,

20
00:00:57,640 --> 00:00:59,600
Speaker 1: so I did want to say that before he started,

21
00:01:00,080 --> 00:01:02,480
Speaker 1: UM in the morning, you didn't say the afternoon. Now

22
00:01:02,520 --> 00:01:06,520
Speaker 1: I'm a little worried. Now I'm just kidding a yeah,

23
00:01:06,760 --> 00:01:09,560
Speaker 1: I wish I could listen all day. UM. Well, the

24
00:01:09,680 --> 00:01:14,039
Speaker 1: last year has been phenomenal on many fronts. UM. Obviously,

25
00:01:14,120 --> 00:01:17,240
Speaker 1: the the opportunity we're going up against has gotten a

26
00:01:17,280 --> 00:01:20,920
Speaker 1: lot more visibility, and we'll talk about what that means

27
00:01:20,920 --> 00:01:23,039
Speaker 1: in the bioeconomy, but it is going to be something

28
00:01:23,080 --> 00:01:25,959
Speaker 1: that I think people start hearing much more about in

29
00:01:26,040 --> 00:01:29,200
Speaker 1: the additional dimension that it adds to the potential of

30
00:01:29,200 --> 00:01:33,679
Speaker 1: our economy and to society at large. UM. The pandemic

31
00:01:33,760 --> 00:01:35,880
Speaker 1: has obviously made it tough for for us, as it

32
00:01:35,920 --> 00:01:39,360
Speaker 1: has for many other companies who are innovating UM. But

33
00:01:39,520 --> 00:01:43,320
Speaker 1: we have very dedicated employees who have been in the

34
00:01:43,400 --> 00:01:48,080
Speaker 1: lab diligently working. We've had our commercial teams diligently preparing

35
00:01:48,160 --> 00:01:51,560
Speaker 1: to to launch our our first commercial product, the Onyx platform,

36
00:01:51,640 --> 00:01:54,080
Speaker 1: which we announced just a few weeks ago that we

37
00:01:54,080 --> 00:01:57,440
Speaker 1: we shipped our our first commercial unit. So UM, we

38
00:01:57,560 --> 00:02:00,400
Speaker 1: are trying to make progress despite the pandemic. We'll tell

39
00:02:00,480 --> 00:02:05,880
Speaker 1: us exactly what the bioeconomy is. Yeah, So, so it

40
00:02:06,040 --> 00:02:08,880
Speaker 1: is UH, as I said, it's to me, it's a

41
00:02:09,080 --> 00:02:12,680
Speaker 1: it's an additional dimension to the economy and new referenced

42
00:02:13,160 --> 00:02:19,520
Speaker 1: at the outset McKenzie statistic. Another statistic from McKenzie last

43
00:02:19,600 --> 00:02:24,960
Speaker 1: year was that in principle, approximately of the physical inputs

44
00:02:24,960 --> 00:02:28,720
Speaker 1: to the economy could be biologically produced. And when you

45
00:02:28,880 --> 00:02:31,120
Speaker 1: sort of take a step back and think about that,

46
00:02:31,120 --> 00:02:34,600
Speaker 1: that explains the magnitude of what we talked about with

47
00:02:34,639 --> 00:02:37,840
Speaker 1: the bioeconomy. Biology has played an important role in the

48
00:02:37,919 --> 00:02:41,639
Speaker 1: last decade on discovery and life sciences and even in

49
00:02:41,960 --> 00:02:46,200
Speaker 1: the production of therapeutics. However, bioeconomy is larger than that.

50
00:02:46,400 --> 00:02:50,280
Speaker 1: It affects many more industries beyond just healthcare, and it

51
00:02:50,320 --> 00:02:54,799
Speaker 1: has much more far reaching impact into products that all

52
00:02:54,840 --> 00:02:57,680
Speaker 1: of us touch every day. And and there's a couple

53
00:02:57,720 --> 00:03:01,079
Speaker 1: of themes that are sort of catalyzing this movement UM

54
00:03:01,120 --> 00:03:03,640
Speaker 1: and some of them are very familiar to us. That

55
00:03:03,800 --> 00:03:10,760
Speaker 1: the movement to sustainability UM, the movement to to climate change,

56
00:03:10,800 --> 00:03:14,120
Speaker 1: to adapt to climate change, and the basic movement around

57
00:03:14,160 --> 00:03:17,720
Speaker 1: just greater performance and efficiency of our of our products

58
00:03:17,720 --> 00:03:22,120
Speaker 1: and businesses. So there are so many confluent catalysts that

59
00:03:22,160 --> 00:03:26,040
Speaker 1: are really accelerating this movement in the bio autonomy. So

60
00:03:26,080 --> 00:03:28,480
Speaker 1: I feel like we're speaking tree and kind of broad

61
00:03:28,720 --> 00:03:31,040
Speaker 1: strokes here. So tell me, like drill it down, like

62
00:03:31,680 --> 00:03:35,440
Speaker 1: does this include things such as growing food and labs,

63
00:03:35,520 --> 00:03:38,120
Speaker 1: growing organs and labs? Like is tell us kind of

64
00:03:38,120 --> 00:03:41,160
Speaker 1: when we get down to a granular, granular level, like

65
00:03:41,280 --> 00:03:45,280
Speaker 1: what exactly this means? So, so the most common things

66
00:03:45,320 --> 00:03:47,400
Speaker 1: that you might read about if you were to Google

67
00:03:47,520 --> 00:03:52,320
Speaker 1: Google it would be UM in agriculture, crops or plants

68
00:03:52,360 --> 00:03:57,400
Speaker 1: that are disease resistant UM that are they're characterized traits

69
00:03:57,480 --> 00:04:01,280
Speaker 1: that allow them UM to to to grow and prosper

70
00:04:01,440 --> 00:04:04,240
Speaker 1: more efficiently. So agriculture is a place where you might

71
00:04:04,320 --> 00:04:06,680
Speaker 1: hear and see this a lot. And as our global

72
00:04:06,720 --> 00:04:10,000
Speaker 1: population grows, as we're trying to get more efficiency out

73
00:04:10,000 --> 00:04:14,160
Speaker 1: of the land and water um in in plants UM.

74
00:04:14,200 --> 00:04:16,600
Speaker 1: This is one area that a lot of companies are

75
00:04:16,600 --> 00:04:21,479
Speaker 1: looking for to see UM innovation and benefit cosmetics. You

76
00:04:21,560 --> 00:04:25,200
Speaker 1: find that that also are starting to talk about using

77
00:04:25,839 --> 00:04:32,160
Speaker 1: UH gene engineering to to manufacture more sustainable UM cosmetic products.

78
00:04:32,800 --> 00:04:34,360
Speaker 1: We also see it if you kind of move back,

79
00:04:34,560 --> 00:04:35,960
Speaker 1: you know, and I said it is beyond healthcare, but

80
00:04:35,960 --> 00:04:38,280
Speaker 1: if you kind of move back to healthcare, even in biologics.

81
00:04:38,400 --> 00:04:40,880
Speaker 1: You know, just today I was talking to a researcher

82
00:04:40,960 --> 00:04:44,520
Speaker 1: in Europe who was very keen in his study of

83
00:04:44,960 --> 00:04:49,920
Speaker 1: antibiotics antibiodetics. Antibiotics haven't really been advanced in the last

84
00:04:49,920 --> 00:04:53,520
Speaker 1: two decades, and many of the organisms in the body

85
00:04:53,560 --> 00:04:57,400
Speaker 1: have have shown resistance to antibiotics. So researchers are studying

86
00:04:57,839 --> 00:05:01,559
Speaker 1: what causes that and can we identify and isolate those

87
00:05:01,600 --> 00:05:03,840
Speaker 1: parts of the genes that contribute to that so that

88
00:05:03,880 --> 00:05:07,280
Speaker 1: we can design more effective antibiotics in the future. So, really,

89
00:05:07,320 --> 00:05:09,599
Speaker 1: as you can tell just such a wide range of

90
00:05:10,080 --> 00:05:13,000
Speaker 1: potential application, I want to get right back to our guest.

91
00:05:13,000 --> 00:05:16,320
Speaker 1: Shree Kasaraju is with us. He's president and CEO of

92
00:05:16,360 --> 00:05:19,680
Speaker 1: the digital genome engineering company is called it SCRIPTA and

93
00:05:19,720 --> 00:05:22,040
Speaker 1: Tree still with us on the phone in San Francisco.

94
00:05:22,320 --> 00:05:24,600
Speaker 1: So Shri, tell us about kind of where your company

95
00:05:24,600 --> 00:05:28,680
Speaker 1: fits into this world of the bioeconomy, what you are

96
00:05:28,720 --> 00:05:33,280
Speaker 1: specifically doing, who you're working with, sure, Carol, So the

97
00:05:33,600 --> 00:05:37,040
Speaker 1: mission for in script is to enable researchers to realize

98
00:05:37,080 --> 00:05:40,640
Speaker 1: the full potential of the bioeconomy, and specifically what that

99
00:05:40,720 --> 00:05:44,560
Speaker 1: means is in our in our first product that we're launching.

100
00:05:45,200 --> 00:05:48,640
Speaker 1: It represents the first digital genome engineering platform in the

101
00:05:48,680 --> 00:05:51,240
Speaker 1: world that can sit on a bench in a lab.

102
00:05:51,839 --> 00:05:57,440
Speaker 1: This initial platform is for microbial so yes Nikoli organisms

103
00:05:57,520 --> 00:05:59,799
Speaker 1: And just to kind of put this in the context,

104
00:06:00,120 --> 00:06:04,040
Speaker 1: can it do a typical experiment, a gene editing experiment

105
00:06:04,120 --> 00:06:06,240
Speaker 1: that a lab may have done with a couple of

106
00:06:06,279 --> 00:06:08,960
Speaker 1: PhDs over the course of many months up to a

107
00:06:09,040 --> 00:06:11,599
Speaker 1: year now can be done in a matter of weeks

108
00:06:11,680 --> 00:06:15,719
Speaker 1: or months and it's an incredible savings of time. But

109
00:06:15,839 --> 00:06:19,760
Speaker 1: more importantly, the scale um of of edits that this

110
00:06:19,960 --> 00:06:22,599
Speaker 1: can produce in a single run can get up to

111
00:06:22,760 --> 00:06:26,719
Speaker 1: ten thousand single edits and parallel, So there's incredible power

112
00:06:26,800 --> 00:06:29,839
Speaker 1: in the scale of this platform UM, and it's really

113
00:06:29,880 --> 00:06:32,680
Speaker 1: opening the minds of many researchers that we speak to

114
00:06:32,760 --> 00:06:35,279
Speaker 1: about what kind of work and research they could do

115
00:06:35,360 --> 00:06:38,719
Speaker 1: with it UM. So that's that's the Onyx platform, and

116
00:06:38,800 --> 00:06:41,800
Speaker 1: behind it UM we're in development on several other very

117
00:06:41,839 --> 00:06:44,440
Speaker 1: exciting platforms as well. Can you talk to us at

118
00:06:44,480 --> 00:06:46,760
Speaker 1: all about some of the partners or the some of

119
00:06:46,760 --> 00:06:48,520
Speaker 1: the areas that you're working in specifically, I know you

120
00:06:48,560 --> 00:06:51,560
Speaker 1: talked about kind of applications of this UM so I'm

121
00:06:51,560 --> 00:06:54,400
Speaker 1: assuming a lot of it is either agg or healthcare.

122
00:06:54,400 --> 00:06:58,680
Speaker 1: I mean, where is it. Well, we're just getting started commercially,

123
00:06:58,680 --> 00:07:01,400
Speaker 1: so we announced our first commercial shipment to gene mill

124
00:07:01,880 --> 00:07:05,119
Speaker 1: UH in the UK in Liverpool. UM. There are two

125
00:07:05,200 --> 00:07:08,680
Speaker 1: main categories of folks that that we're talking to right

126
00:07:08,720 --> 00:07:12,200
Speaker 1: now about about the platform. One is your your core

127
00:07:12,240 --> 00:07:17,000
Speaker 1: academic research centers and to our our bio industrial companies

128
00:07:17,000 --> 00:07:20,240
Speaker 1: and the range of industries that that represents your your right.

129
00:07:20,320 --> 00:07:22,720
Speaker 1: You know, it's a it's a very wide range, UM.

130
00:07:22,800 --> 00:07:26,480
Speaker 1: And but many of these folks are already utilizing Crisper

131
00:07:26,840 --> 00:07:29,800
Speaker 1: in some way, meaning they're doing some form of gene

132
00:07:29,920 --> 00:07:33,240
Speaker 1: editing UM in house already UM. And they're looking to

133
00:07:33,520 --> 00:07:37,440
Speaker 1: to really make those experiments more efficient, but also explore

134
00:07:38,000 --> 00:07:40,240
Speaker 1: what more can they do with a more powerful system

135
00:07:40,240 --> 00:07:44,000
Speaker 1: and platform. So, Okay, forgive me because I'm thinking we've

136
00:07:44,000 --> 00:07:45,560
Speaker 1: got a lot of listeners and we have a really

137
00:07:45,560 --> 00:07:49,240
Speaker 1: smart audience. UM. And I'm gonna unt this is not

138
00:07:49,320 --> 00:07:52,320
Speaker 1: my world, but it definitely interests interests me in terms

139
00:07:52,320 --> 00:07:55,000
Speaker 1: of gene editing and kind of where this is all going. So,

140
00:07:55,040 --> 00:07:57,200
Speaker 1: if you were sitting down with someone to explain kind

141
00:07:57,200 --> 00:08:00,520
Speaker 1: of the potential because it sounds like we're on the

142
00:08:00,560 --> 00:08:03,160
Speaker 1: cusp Uh, there's a lot out there already, but there's

143
00:08:03,160 --> 00:08:04,800
Speaker 1: so much more that could be done when it comes

144
00:08:04,840 --> 00:08:08,640
Speaker 1: to the bioeconomy or uh, the genomic engineering that you

145
00:08:08,640 --> 00:08:11,720
Speaker 1: guys are involved in. UM, how would you explain it

146
00:08:11,800 --> 00:08:13,960
Speaker 1: kind of to a lay person in terms of how

147
00:08:14,000 --> 00:08:16,920
Speaker 1: it might impact us in the years to come? Also

148
00:08:17,040 --> 00:08:20,280
Speaker 1: as an investor kind of who will be the players

149
00:08:20,320 --> 00:08:22,080
Speaker 1: involved in it? Because I am curious about kind of

150
00:08:22,120 --> 00:08:25,640
Speaker 1: your own future. Yeah, sure, yeah, that's a great question.

151
00:08:25,680 --> 00:08:29,160
Speaker 1: So to put this into context, if we think about genomics,

152
00:08:29,400 --> 00:08:32,720
Speaker 1: and even with COVID, we've heard about some of these

153
00:08:32,840 --> 00:08:36,280
Speaker 1: terms of the technologies that are being used. PCR and

154
00:08:36,360 --> 00:08:39,880
Speaker 1: next gen sequencing are amongst some of the biggest step

155
00:08:39,920 --> 00:08:42,520
Speaker 1: function changes in our history as it relates to genomics,

156
00:08:42,559 --> 00:08:46,160
Speaker 1: and those are all around reading genes and that's provided

157
00:08:46,240 --> 00:08:49,640
Speaker 1: us incredible information. We've utilized it in a variety of

158
00:08:49,679 --> 00:08:54,439
Speaker 1: ways for research, even trying to develop UM diagnostics or

159
00:08:54,559 --> 00:08:57,320
Speaker 1: or even things to fight things like the US the

160
00:08:57,400 --> 00:09:02,600
Speaker 1: COVID nineteen virus. What what what Cristper has done is

161
00:09:02,640 --> 00:09:07,480
Speaker 1: provided a step function change against those prior historical advancements

162
00:09:07,559 --> 00:09:12,640
Speaker 1: Now with Crisper, we can edit genes. We can write

163
00:09:12,760 --> 00:09:16,600
Speaker 1: genes instead of reading them, and that the opportunity around

164
00:09:16,640 --> 00:09:19,920
Speaker 1: that is massive. When you when we speak to researchers,

165
00:09:20,080 --> 00:09:23,280
Speaker 1: they're trying to create as much they call it variation.

166
00:09:23,400 --> 00:09:25,960
Speaker 1: That means as much things to study around, something to

167
00:09:26,120 --> 00:09:29,880
Speaker 1: learn as possible. But it's not just about research and information.

168
00:09:29,920 --> 00:09:33,960
Speaker 1: Now with with gene editing, we can also create new products.

169
00:09:34,280 --> 00:09:37,280
Speaker 1: And that's the biggest change with this advancement of what

170
00:09:37,840 --> 00:09:40,079
Speaker 1: we in script as well as others are going to

171
00:09:40,160 --> 00:09:43,080
Speaker 1: be doing, as we're not only going to be understanding information,

172
00:09:43,160 --> 00:09:46,080
Speaker 1: but we're going to be creating products um with this

173
00:09:46,160 --> 00:09:49,920
Speaker 1: technology as well. And that is where the breath of

174
00:09:49,960 --> 00:09:54,760
Speaker 1: the opportunity is just so incredibly massive that that we're

175
00:09:54,800 --> 00:09:57,280
Speaker 1: all quite excited about it. Well, So tell us about

176
00:09:57,320 --> 00:10:01,240
Speaker 1: this billion dollar Series E finance round. I think it

177
00:10:01,280 --> 00:10:04,679
Speaker 1: was led by Fidelity. There's also funds and accounts from

178
00:10:04,720 --> 00:10:06,600
Speaker 1: t ro Price that are involved in it. Tell us

179
00:10:06,600 --> 00:10:08,880
Speaker 1: about that and and that kind of that money. What

180
00:10:08,920 --> 00:10:12,480
Speaker 1: will you guys plan to do with it? This this

181
00:10:12,600 --> 00:10:15,280
Speaker 1: is a just an incredible market I know, you know

182
00:10:15,400 --> 00:10:18,920
Speaker 1: all the listeners know that from watching the market environment

183
00:10:18,960 --> 00:10:22,760
Speaker 1: we're in and seeing the premium for for innovation and

184
00:10:22,800 --> 00:10:27,800
Speaker 1: growth companies UM, and specifically in in the life sciences.

185
00:10:27,840 --> 00:10:30,000
Speaker 1: You know, this whole area of gene editing also has

186
00:10:30,040 --> 00:10:33,840
Speaker 1: been extremely robust and a lot of capital going against

187
00:10:33,880 --> 00:10:36,560
Speaker 1: it because there's a lot to do. UM. We we

188
00:10:36,640 --> 00:10:40,160
Speaker 1: looked at this round as as an opportunistic financing UM.

189
00:10:40,240 --> 00:10:42,520
Speaker 1: We were well capitalized. UM. There are a lot of

190
00:10:42,520 --> 00:10:45,880
Speaker 1: alternatives for companies to raise money to go public. UM.

191
00:10:45,960 --> 00:10:47,920
Speaker 1: We think we got the best of both worlds. We

192
00:10:48,040 --> 00:10:52,000
Speaker 1: got really world class long term investors, and we also

193
00:10:52,160 --> 00:10:55,720
Speaker 1: retain the ability to to grow our business privately, you know,

194
00:10:55,760 --> 00:11:00,160
Speaker 1: which affords tremendous flexibility UM and the opportunity to to

195
00:11:00,320 --> 00:11:02,400
Speaker 1: explore new areas. And so the hundred and fifty million

196
00:11:02,440 --> 00:11:05,280
Speaker 1: dollars you know, I use the word opportunistic, it's really

197
00:11:05,320 --> 00:11:09,040
Speaker 1: around going after additional areas that where we can bring

198
00:11:09,040 --> 00:11:12,319
Speaker 1: our technology UM to more and more researchers. So those

199
00:11:12,320 --> 00:11:15,160
Speaker 1: are these are things down the road beyond what we're

200
00:11:15,280 --> 00:11:19,000
Speaker 1: already developing with either Onyx or our Mammalian platform. What

201
00:11:19,200 --> 00:11:21,480
Speaker 1: is the growth of the company do you I mean,

202
00:11:21,480 --> 00:11:25,680
Speaker 1: I know you're early in what are your expectations going forward,

203
00:11:27,320 --> 00:11:31,800
Speaker 1: this is such as we've established such a large market.

204
00:11:32,080 --> 00:11:36,640
Speaker 1: The the focus for for us is exactly that, having focus,

205
00:11:36,720 --> 00:11:41,240
Speaker 1: picking certain areas and customers and really showing success of

206
00:11:41,280 --> 00:11:44,600
Speaker 1: our platform. So it might be contra to what someone

207
00:11:44,679 --> 00:11:47,720
Speaker 1: might think about, you know, really growing going fast and

208
00:11:47,760 --> 00:11:52,280
Speaker 1: growing fast for us that the long term future gets

209
00:11:52,320 --> 00:11:56,440
Speaker 1: solidified and much stronger if we can be successful showing

210
00:11:56,480 --> 00:12:00,480
Speaker 1: customers applications where they can use this technology, gene where

211
00:12:00,480 --> 00:12:03,840
Speaker 1: they can do things they haven't done before. So when

212
00:12:03,880 --> 00:12:05,960
Speaker 1: we look at this, and when I think our investors

213
00:12:06,000 --> 00:12:07,840
Speaker 1: who got involved in the series, he looked at this,

214
00:12:08,320 --> 00:12:15,600
Speaker 1: it wasn't about driving um platform revenues or sales, you know,

215
00:12:15,679 --> 00:12:18,600
Speaker 1: this was about how do we secure our place as

216
00:12:18,679 --> 00:12:23,320
Speaker 1: a long term impact you know that can drive a

217
00:12:23,360 --> 00:12:26,960
Speaker 1: new paradigm change, not just for the technology but for

218
00:12:27,040 --> 00:12:29,800
Speaker 1: us as an organization. You know, they they've encouraged us

219
00:12:29,800 --> 00:12:32,600
Speaker 1: to be aggressive and invest um and to take our

220
00:12:32,640 --> 00:12:35,760
Speaker 1: time making good decisions. You know that that aren't necessarily

221
00:12:35,760 --> 00:12:39,200
Speaker 1: short term oriented, but can drive greater long term stability

222
00:12:39,240 --> 00:12:41,360
Speaker 1: and success. We think this is going to be a

223
00:12:42,200 --> 00:12:46,400
Speaker 1: new large market and so being early, being smart about

224
00:12:46,440 --> 00:12:49,360
Speaker 1: how we build a company for the future are our paramount. Well,

225
00:12:49,400 --> 00:12:51,040
Speaker 1: we look forward to hearing more and I hope you'll

226
00:12:51,080 --> 00:12:53,200
Speaker 1: come back and by then, hopefully I will have your

227
00:12:53,320 --> 00:12:57,840
Speaker 1: name down Pat Tree uh Kosaraju. He is the President

228
00:12:57,920 --> 00:13:01,319
Speaker 1: CEO of the Digital Genome Engineering cow Bunny in Scripta

229
00:13:01,400 --> 00:13:04,000
Speaker 1: and we appreciate his time. Shares it Dell by the

230
00:13:04,000 --> 00:13:05,840
Speaker 1: way up about eight point four percent, and the after

231
00:13:05,920 --> 00:13:08,400
Speaker 1: hours saying it's going to spin on em Ware software

232
00:13:08,480 --> 00:13:11,640
Speaker 1: unit by the fourth quarter. Have a good and safe evening, everybody.

233
00:13:11,800 --> 00:13:12,839
Speaker 1: This is Bloomberg